Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Targeting specific enzyme reverses radiation-induced immune suppression in cancer

Researchers at the University of Chicago identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them.

30 Oct 2026

Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment

Patients with an advanced form of lung cancer lived 56 percent longer without their disease progressing when radiotherapy was added to the standard of care whole-body therapy, including chemotherapy and/or immunotherapy, according to initial results from a clinical trial presented at the 2026 European Society for Medical Oncology (ESMO) Congress.

27 Oct 2026

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

26 Oct 2026

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

26 Oct 2026

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer cells, slow tumor growth and limit the cancer's spread. Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) developed the approach.

23 Oct 2026

Study identifies potential treatment target for aggressive lung tumors

A UTHealth Houston-led team has identified a promising new avenue to curb the growth and spread of tumors associated with hard-to-treat lung and other cancers.

20 Oct 2026

Invisible no more: New treatment avenue unlocked for deadliest lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally.

16 Oct 2026

WEHI study reveals a new immune pathway for fighting small cell lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally.

14 Oct 2026

Scientists studied diet and lung cancer in 95,612 adults. One eating pattern stood out

A prospective study of 95,612 U.S. adults found that those with the highest sulfur microbial diet scores had a 23% higher adjusted lung cancer incidence hazard and a 19% higher lung cancer-related mortality hazard than those with the lowest scores. However, the associations weakened after accounting for overall dietary quality and competing causes of death, and the findings do not establish a causal relationship.

13 Oct 2026

Cigarette smoke alters lung stem cells to drive specific cancers

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

6 Oct 2026

Focused radiosurgery extends survival for small cell lung cancer patients with brain metastases

Patients with small cell lung cancer (SCLC) that had spread to the brain lived a median of 17 months after focused stereotactic radiosurgery, compared with nine months after an advanced form of whole brain radiation therapy, an unexpected secondary finding from the first randomized phase 3 trial to compare the treatment approaches in this population.

28 Sep 2026

AI model predicts immunotherapy-related pneumonitis risk from CT scans

Researchers at The University of Texas MD Anderson Cancer Center have developed an artificial intelligence (AI) model that can identify lung cancer patients at increased risk of developing a serious immunotherapy-related side effect before treatment begins, offering a possible path toward more personalized monitoring and prevention strategies.

24 Sep 2026

Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026

Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.

From Diaceutics PLC 18 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

AI tools help predict immunotherapy outcomes in lung cancer patients

Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine.

16 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Patients with metastatic non-small cell lung cancer (NSCLC) harboring class II and class III BRAF alterations have distinct clinicopathologic and genomic characteristics, with class III alterations potentially associated with worse prognosis, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Small Cell Lung Cancer News and Research

Targeting specific enzyme reverses radiation-induced immune suppression in cancer

Patients with a form of advanced lung cancer lived 56 percent longer without their disease progressing after receiving radiotherapy in addition to standard treatment

Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

Dual-targeted therapy shows promise against metastatic triple-negative breast cancer

Study identifies potential treatment target for aggressive lung tumors

Invisible no more: New treatment avenue unlocked for deadliest lung cancer

WEHI study reveals a new immune pathway for fighting small cell lung cancer

Scientists studied diet and lung cancer in 95,612 adults. One eating pattern stood out

Cigarette smoke alters lung stem cells to drive specific cancers

Focused radiosurgery extends survival for small cell lung cancer patients with brain metastases

AI model predicts immunotherapy-related pneumonitis risk from CT scans

Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

AI tools help predict immunotherapy outcomes in lung cancer patients

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Research identifies novel prognostic biomarkers for class II and III BRAF-altered cancers

Early consolidative SRT shows value in EGFR-mutant NSCLC with limited brain metastases

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Zipalertinib plus chemotherapy improves survival in advanced NSCLC harboring EGFR exon 20 insertion mutations

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News